Botulinum toxin A (BTA) is considered an effective treatment of blepharospasm and hemifacial spasm, but there are few studies to permit a comparison of its different formulations. This prospective, randomized, double-blind study compared Prosigne, a BTA of Chinese origin, with Botox to establish safety, efficacy, and equivalence of doses between those 2 formulations in blepharospasm and hemifacial spasm treatment. Fifty-seven patients participated in this study: 21 blepharospasm (from whom 11 were treated with Botox; and 10, with Prosigne) and 36 hemifacial spasm patients (17 were treated with Botox; and 19, with Prosigne). All patients were similar in age, disease time span, number of previous shots, and time elapsed since the last BTA application. Pain and burning during the injection and the result of the treatment were similar in both groups. There were no systemic adverse events, and the local ones were observed with similar intensity and frequency for both groups. The mean effect time length was similar for both blepharospasm (11.3 weeks for both toxins) and hemifacial spasm patients (12.8 weeks for Botox and 12.9 weeks for Prosigne). In both blepharospasm groups, only the 36-Item Short-Form Health Survey emotional aspects domain showed improvement from baseline after 16 weeks. There were no differences between the 36-Item Short-Form Health Survey scores before and after the treatment of all hemifacial spasm patients. Therefore, it has been concluded that Botox and Prosigne have similar efficacy, safety, and tolerability profiles, so that a dose equivalence of 1:1 may be considered for blepharospasm and hemifacial spasm treatments. © 2010 by Lippincott Williams & Wilkins.3312731Defazio, G., Livrea, P., Epidemiology of primary blepharoespasm (2002) Mov Disord, 17, pp. 7-12Brin, M.F., Danisi, F., Blitzer, A., Blepharospasm, oromandibular dystonia, Meige's syndrome and hemifacial spasm (2003) Handbook of Botulinum Toxin Treatment, 6, pp. 119-141. , Moore P, Naumann M, eds. 2nd ed. Blackwell ScienceJankovic, J., Treatment of dystonia (2004) Movement Disorders, 32, pp. 527-539. , Watts RL, Koller, eds. 2nd ed. New York, NY: McGraw-HillCosta, J., Espírito-Santo, C., Borges, A., Botulinum toxin type A therapy for blepharospasm (2005) Cochrane Database of Systematic Reviews, (1). , DOI: 10.1002/ 14651858.CD004900.pub2, Art No: CD004900Simpson, D.M., Blitzer, A., Brashear, A., Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2008) Neurology, 70, pp. 1699-1706Campos-Benitez, M., Kaufmann, A.M., Neurovascular compression findings in hemifacial spasm (2008) J Neurosurg, pp. 416-420. , 109930Tankéré, F., Bernat, I., Bells palsy: From viral aetiology to diagnostic reality [in French] (2009) Rev Med Interne, 30, pp. 769-775Scott, N.A., Kennedy, R.A., Stubbs, H.A., Botulinum A toxin injections as a treatment for blepharospasm (1985) Arch Ophthalmol, 103, pp. 347-350Schantz, E.J., Johnson, E.A., Properties and use of botulinum toxin and other microbial neurotoxins in medicine (1992) Microbiol Rev, 56 (1), pp. 80-99Rossetto, O., Caccin, P., Rigoni, M., The metalloprotease activity of tetanus and botulinum neurotoxins (2002) Scientific and Therapeutic Aspects of Botulinum Toxin, 1, pp. 3-10. , Brin MF, Jankovic J, Hallett M, eds. Philadelphia, PA: Lippincott Williams & WilkinsWan, X., Tang, X., Cui, L., Remote effects of local injection of botulinum toxin type A (1999) Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 21 (5), pp. 362-367Dressler, D., Bigalke, H., Rothwell, J.C., The sternocleidomastoid test: An in vivo assay to investigate botulinum toxin antibody formation in humans (2000) J Neurol, 247 (8), pp. 630-632Bogucki, A., Serial SFEMG studies of orbicularis muscle after first administration of botulinum toxin (1999) Eur J Neurol, 6, pp. 461-467Tang, X., Wan, X., Comparison of Botox with a Chinese type A botulinum toxin (2000) Chin Med J (Engl), 113 (9), pp. 794-798Roggenkamper, P., Jost, W.H., Bihari, K., Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm (2006) J Neural Transm, 113, pp. 303-312Rieder, C.R.M., Schestatsky, P., Socal, M.P., A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm (2007) Clin Neuropharmacol, 30 (1), pp. 39-42Wang, Y.C., Zhuang, H., Huang, B.G., Preparation of type A botulinum crystalline toxin for the therapeutic and establishment of an experimental animal model (1990) J Biol Prod, 3 (3), pp. 121-125Dai, Z., Lu, W., Wu, X., Phase II clinical trial of treatment of blepharospasm, hemifacial spasm with botulinum toxin type A for injection (1993) China J Ophthalmol, 29 (3), pp. 144-145Zhang, L.J., Feng, X.L., Zhang, S.M., A study on botulinum toxin A in treatment of blepharospasm and facial spasm (1998) Shanxi Med J, 27 (1), pp. 50-51Zhao, C.D., Chen, H.X., Nie, Z.M., A clinical study of botulinum toxin type A in treatment of blepharospasm and facial spasm (1996) China J Nerv Ment Dis, 22 (2), pp. 83-85Sampaio, C., DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type AVDysport and BotoxVassuming a ratio of 4: 1 (1997) Mov Disord, 12 (6), pp. 1013-1018Lasalvia, C.G., Pereira, L.D.S., Da Cunha, M.C., Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm (2006) Arq Bras Oftalmol, 69 (5), pp. 701-705Girlanda, P., Quartarone, A., Sinicropi, S., Unilateral injection of botulinum toxin in blepharospasm: Single fiber electromyography and blink reflex study (1996) Mov Disord, 11, pp. 27-31Walpole, R.E., Myers, R.H., Meyers, S.L., (2007) Probability and Statistics for Engineers and Scientists, , 8th ed. Pearson Prentice HallMauriello Jr., J.A., The role of botulinum toxin type A in the management of blepharospasm and hemifacial spasm (2002) Scientific and Therapeutic Aspects of Botulinum Toxin, 19, pp. 197-205. , Brin MF, Jankovic J, Hallett M, eds. Philadelphia, PA: Lippincott Williams & Wilkins